Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Objective response is a weak surrogate of activity in phase II trials, since in most cases, the predominant effect of these compounds is basically cytostatic.
客观反映在II期试验中只是一个活性的微弱代表，因为在大多病例中，这些组合的主要作用是以细胞抑制为基础的。
应用推荐